{"pmid":32396627,"title":"Successful percutaneous thrombectomy in a patient with COVID-19 pneumonia and acute pulmonary embolism supported by extracorporeal membrane oxygenation.","text":["Successful percutaneous thrombectomy in a patient with COVID-19 pneumonia and acute pulmonary embolism supported by extracorporeal membrane oxygenation.","Eur Heart J","Schmiady, Martin O","Sromicki, Juri","Kucher, Nils","Ouda, Ahmed","32396627"],"journal":"Eur Heart J","authors":["Schmiady, Martin O","Sromicki, Juri","Kucher, Nils","Ouda, Ahmed"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396627","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/eurheartj/ehaa403","topics":["Case Report"],"weight":1,"_version_":1666627827930234881,"score":9.490897,"similar":[{"pmid":32271455,"title":"Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report.","text":["Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report.","Since the end of 2019, COVID-19 has been prevalent in Wuhan, China, and has been rapidly spreading to mainland China. Currently, more than 80,000 people have been infected, of which over 10,000 were severely ill and had characteristics of dyspnea and hypoxemia about one week after onset. Severe patients had rapidly progressed to acute respiratory distress syndrome (ARDS), causing multiple organ failures and even death, with a mortality rate of nearly 4.3%. The treatment of severe COVID-19 patients has been rarely reported. This study reported a successful example of a severe COVID-19 patient with extracorporeal membrane oxygenation (ECMO) technology in our hospital. This experience revealed that the early application of ECMO can dramatically promote the recovery of severe COVID-19 patients.","Eur Rev Med Pharmacol Sci","Zhan, W-Q","Li, M-D","Xu, M","Lu, Y-B","32271455"],"abstract":["Since the end of 2019, COVID-19 has been prevalent in Wuhan, China, and has been rapidly spreading to mainland China. Currently, more than 80,000 people have been infected, of which over 10,000 were severely ill and had characteristics of dyspnea and hypoxemia about one week after onset. Severe patients had rapidly progressed to acute respiratory distress syndrome (ARDS), causing multiple organ failures and even death, with a mortality rate of nearly 4.3%. The treatment of severe COVID-19 patients has been rarely reported. This study reported a successful example of a severe COVID-19 patient with extracorporeal membrane oxygenation (ECMO) technology in our hospital. This experience revealed that the early application of ECMO can dramatically promote the recovery of severe COVID-19 patients."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Zhan, W-Q","Li, M-D","Xu, M","Lu, Y-B"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271455","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20705","locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138491797372930,"score":72.018715},{"pmid":32462990,"title":"COVID-19 complicated by pulmonary embolism treated with catheter directed thrombectomy.","text":["COVID-19 complicated by pulmonary embolism treated with catheter directed thrombectomy.","COVID-19 is a recently identified illness that is associated with thromboembolic events. We report a case of pulmonary embolism in a patient with COVID-19, treated by catheter directed thrombectomy. A 57 year old patient presented to the emergency center with severe COVID-19 symptoms and developed massive pulmonary embolism. The patient was treated with catheter directed thrombolysis (CDT) and recovered completely. Coagulopathy associated with COVID-19 is present in all severe cases and is a dynamic process. We describe a case of massive/high risk pulmonary embolism, in a patient with COVID-19 receiving full anticoagulation, who was treated by percutaneous intervention. CDT can be an additional therapeutic option in patients with COVID-19 and pulmonary embolism that present with rapid clinical collapse.","Vasa","Galastri, Francisco Leonardo","Valle, Leonardo Guedes Moreira","Affonso, Breno Boueri","Silva, Marcela Juliano","Garcia, Rodrigo Gobbo","Junior, Milton Rodrigues","Ferraz, Leonardo Jose Rolim","de Matos, Gustavo Faissol Janot","de la Cruz Scarin, Farah Christina","Nasser, Felipe","32462990"],"abstract":["COVID-19 is a recently identified illness that is associated with thromboembolic events. We report a case of pulmonary embolism in a patient with COVID-19, treated by catheter directed thrombectomy. A 57 year old patient presented to the emergency center with severe COVID-19 symptoms and developed massive pulmonary embolism. The patient was treated with catheter directed thrombolysis (CDT) and recovered completely. Coagulopathy associated with COVID-19 is present in all severe cases and is a dynamic process. We describe a case of massive/high risk pulmonary embolism, in a patient with COVID-19 receiving full anticoagulation, who was treated by percutaneous intervention. CDT can be an additional therapeutic option in patients with COVID-19 and pulmonary embolism that present with rapid clinical collapse."],"journal":"Vasa","authors":["Galastri, Francisco Leonardo","Valle, Leonardo Guedes Moreira","Affonso, Breno Boueri","Silva, Marcela Juliano","Garcia, Rodrigo Gobbo","Junior, Milton Rodrigues","Ferraz, Leonardo Jose Rolim","de Matos, Gustavo Faissol Janot","de la Cruz Scarin, Farah Christina","Nasser, Felipe"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462990","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1024/0301-1526/a000880","keywords":["covid-19","anticoagulants","mechanical thrombolysis","pulmonary embolism","thrombectomy"],"topics":["Case Report"],"weight":1,"_version_":1668079521301004288,"score":61.316147},{"pmid":32472827,"title":"First Successful Treatment of Coronavirus Disease 2019 Induced Refractory Cardiogenic Plus Vasoplegic Shock by Combination of Percutaneous Ventricular Assist Device and Extracorporeal Membrane Oxygenation: A Case Report.","text":["First Successful Treatment of Coronavirus Disease 2019 Induced Refractory Cardiogenic Plus Vasoplegic Shock by Combination of Percutaneous Ventricular Assist Device and Extracorporeal Membrane Oxygenation: A Case Report.","The novel coronavirus severe acute respiratory syndrome coronavirus 2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease 2019 (COVID-19) is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac, and kidney injury as well as shock. Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with adult respiratory distress syndrome plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device plus an extracorporeal membrane oxygenation. Although such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients.","ASAIO J","Bemtgen, Xavier","Kruger, Kirsten","Supady, Alexander","Duerschmied, Daniel","Schibilsky, David","Bamberg, Fabian","Bode, Christoph","Wengenmayer, Tobias","Staudacher, Dawid L","32472827"],"abstract":["The novel coronavirus severe acute respiratory syndrome coronavirus 2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease 2019 (COVID-19) is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac, and kidney injury as well as shock. Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with adult respiratory distress syndrome plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device plus an extracorporeal membrane oxygenation. Although such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients."],"journal":"ASAIO J","authors":["Bemtgen, Xavier","Kruger, Kirsten","Supady, Alexander","Duerschmied, Daniel","Schibilsky, David","Bamberg, Fabian","Bode, Christoph","Wengenmayer, Tobias","Staudacher, Dawid L"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472827","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/MAT.0000000000001178","topics":["Case Report"],"weight":1,"_version_":1668255193337167872,"score":60.15271},{"pmid":32313662,"pmcid":"PMC7161844","title":"Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan.","text":["Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan.","Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is one of the ultimate treatments for acute respiratory failure. However, the effectiveness of ECMO in patients with novel coronavirus disease (COVID-19) is unknown. Case Presentation: A 72-year-old woman who was a passenger of a cruise ship tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while in quarantine on board using throat swab. Three days after admission, her condition deteriorated, and she was subsequently intubated. On day 6, VV-ECMO was introduced. Lopinavir/ritonavir was given; continuous renal replacement therapy was also introduced. On day 10, her chest radiography and lung compliance improved. She was weaned off ECMO on day 12. Conclusion: Treatment of severe pneumonia in COVID-19 by ECMO should recognize lung plasticity considering time to ECMO introduction and interstitial biomarkers. In Japan, centralization of ECMO patients has not been sufficient. Thus, we suggest nationwide centralization and further research to respond to the crisis caused by COVID-19.","Acute Med Surg","Taniguchi, Hayato","Ogawa, Fumihiro","Honzawa, Hiroshi","Yamaguchi, Keishi","Niida, Shoko","Shinohara, Mafumi","Takahashi, Kohei","Iwashita, Masayuki","Abe, Takeru","Kubo, Sousuke","Kudo, Makoto","Takeuchi, Ichiro","32313662"],"abstract":["Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is one of the ultimate treatments for acute respiratory failure. However, the effectiveness of ECMO in patients with novel coronavirus disease (COVID-19) is unknown. Case Presentation: A 72-year-old woman who was a passenger of a cruise ship tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while in quarantine on board using throat swab. Three days after admission, her condition deteriorated, and she was subsequently intubated. On day 6, VV-ECMO was introduced. Lopinavir/ritonavir was given; continuous renal replacement therapy was also introduced. On day 10, her chest radiography and lung compliance improved. She was weaned off ECMO on day 12. Conclusion: Treatment of severe pneumonia in COVID-19 by ECMO should recognize lung plasticity considering time to ECMO introduction and interstitial biomarkers. In Japan, centralization of ECMO patients has not been sufficient. Thus, we suggest nationwide centralization and further research to respond to the crisis caused by COVID-19."],"journal":"Acute Med Surg","authors":["Taniguchi, Hayato","Ogawa, Fumihiro","Honzawa, Hiroshi","Yamaguchi, Keishi","Niida, Shoko","Shinohara, Mafumi","Takahashi, Kohei","Iwashita, Masayuki","Abe, Takeru","Kubo, Sousuke","Kudo, Makoto","Takeuchi, Ichiro"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313662","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ams2.509","keywords":["coronavirus disease 2019","japan","extracorporeal membrane oxygenation","lopinavir","ritonavir","severe acute respiratory syndrome coronavirus 2"],"locations":["Veno","Japan","Japan"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"e_drugs":["lopinavir-ritonavir drug combination"],"topics":["Case Report"],"weight":1,"_version_":1666138493461463040,"score":58.206112},{"pmid":32470179,"title":"Management of Upper Airway Bleeding in COVID-19 Patients on Extracorporeal Membrane Oxygenation.","text":["Management of Upper Airway Bleeding in COVID-19 Patients on Extracorporeal Membrane Oxygenation.","Laryngoscope","LoSavio, Phillip S","Patel, Tirth","Urban, Matthew J","Tajudeen, Bobby","Papagiannopoulos, Peter","Revenaugh, Peter C","Husain, Inna","Batra, Pete S","32470179"],"journal":"Laryngoscope","authors":["LoSavio, Phillip S","Patel, Tirth","Urban, Matthew J","Tajudeen, Bobby","Papagiannopoulos, Peter","Revenaugh, Peter C","Husain, Inna","Batra, Pete S"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470179","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/lary.28846","keywords":["airway","bleeding","covid-19","coronavirus","epistaxis","extracorporeal membrane oxygenation","hemorrhage"],"topics":["Case Report"],"weight":1,"_version_":1668167109956337665,"score":56.80979}]}